Taking people in GermanyPhase 1/2
Tests PXS-5505 with azacitidine in people with myelodysplastic syndrome or CMML
Tests PXS-5505 with azacitidine in adults with myelodysplastic syndrome or CMML.
Plain-language title generated from the registry record
Registry title: AZALOX Study: Safety and Efficacy of PXS-5505 with 5-Azacitidine in MDS and CMML Patients
Key facts
- Where
- Bonn, Dresden, Duesseldorf, Goettingen, Hanover, Luebeck, Mainz, Mannheim, Munich, and Oldenburg, GermanySee the 10 sites
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with myelodysplastic neoplasms (MDS) or chronic myelomonocytic leukemia (CMML). It tests PXS-5505 together with 5-azacitidine.
- Age
- 18 years or older
- Sex
- All sexes can join.
Read by machine on 9 November 2026.
Where in Germany
- Universitaetsklinikum Bonn AöRBonn, GermanyTaking people
- Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöRDresden, GermanyTaking people
- Universitaetsklinikum Duesseldorf AöRDuesseldorf, GermanyTaking people
- Universitaetsmedizin GoettingenGoettingen, GermanyTaking people
- Medizinische Hochschule HannoverHanover, GermanyTaking people
- Universitaetsklinikum Schleswig-Holstein AöRLuebeck, GermanyTaking people
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöRMainz, GermanyTaking people
- Heidelberg UniversityMannheim, GermanyTaking people
- Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)Munich, GermanyTaking people
- Klinikum Oldenburg AorOldenburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Heidelberg University
- Trial code
- EU 2024-517237-40-00
- Record updated
- 16 October 2026